EP3528810A4 - BROMDOMAIN INHIBITOR - Google Patents

BROMDOMAIN INHIBITOR Download PDF

Info

Publication number
EP3528810A4
EP3528810A4 EP17862619.8A EP17862619A EP3528810A4 EP 3528810 A4 EP3528810 A4 EP 3528810A4 EP 17862619 A EP17862619 A EP 17862619A EP 3528810 A4 EP3528810 A4 EP 3528810A4
Authority
EP
European Patent Office
Prior art keywords
bromodomain inhibitor
bromodomain
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17862619.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3528810A1 (en
Inventor
Juan Manuel Betancort
Jeffrey Alan Stafford
Ryan STANSFIELD
James Marvin Veal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Quanticel Research Inc
Original Assignee
Celgene Quanticel Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research Inc filed Critical Celgene Quanticel Research Inc
Publication of EP3528810A1 publication Critical patent/EP3528810A1/en
Publication of EP3528810A4 publication Critical patent/EP3528810A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP17862619.8A 2016-10-20 2017-10-19 BROMDOMAIN INHIBITOR Withdrawn EP3528810A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662410756P 2016-10-20 2016-10-20
PCT/US2017/057439 WO2018075796A1 (en) 2016-10-20 2017-10-19 Bromodomain inhibitor

Publications (2)

Publication Number Publication Date
EP3528810A1 EP3528810A1 (en) 2019-08-28
EP3528810A4 true EP3528810A4 (en) 2020-06-17

Family

ID=62019669

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17862619.8A Withdrawn EP3528810A4 (en) 2016-10-20 2017-10-19 BROMDOMAIN INHIBITOR

Country Status (7)

Country Link
EP (1) EP3528810A4 (enExample)
JP (3) JP7129973B2 (enExample)
CN (1) CN110099685A (enExample)
AR (1) AR109859A1 (enExample)
AU (1) AU2017345468B2 (enExample)
TW (1) TW201821062A (enExample)
WO (1) WO2018075796A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
TW201642860A (zh) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
AU2019309693B2 (en) * 2018-07-23 2023-03-16 Celgene Quanticel Research, Inc. Process for the preparation of bromodomain inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015058160A1 (en) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors
WO2016172618A1 (en) * 2015-04-22 2016-10-27 Celgene Quanticel Research, Inc. Bromodomain inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN105899212A (zh) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法
US9884806B2 (en) * 2013-08-30 2018-02-06 Icahn School Of Medicine At Mount Sinai Cyclic vinylogous amides as bromodomain inhibitors
JP2016538310A (ja) * 2013-11-27 2016-12-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法
CN105732624B (zh) * 2016-01-28 2019-08-02 中国药科大学 吡咯[4,3,2-de]喹啉-2(1H)-酮类BRD4蛋白抑制剂的制备方法及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015058160A1 (en) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors
WO2016172618A1 (en) * 2015-04-22 2016-10-27 Celgene Quanticel Research, Inc. Bromodomain inhibitor

Also Published As

Publication number Publication date
TW201821062A (zh) 2018-06-16
AU2017345468B2 (en) 2022-06-02
WO2018075796A1 (en) 2018-04-26
JP2024056905A (ja) 2024-04-23
EP3528810A1 (en) 2019-08-28
AU2017345468A1 (en) 2019-06-06
CN110099685A (zh) 2019-08-06
AR109859A1 (es) 2019-01-30
JP7129973B2 (ja) 2022-09-02
JP2022095897A (ja) 2022-06-28
JP2019535671A (ja) 2019-12-12

Similar Documents

Publication Publication Date Title
MA52814A (fr) Inhibiteurs de bromodomaine
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
EP3283077A4 (en) BROMDOMÄNENINHIBITOREN
DK3627029T3 (da) Manipulationssikret låg
DK3405050T3 (da) Børnesikret snusbeholder
EP3541820A4 (en) MAGL INHIBITORS
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
MA46857A (fr) Inhibiteurs de magl
DK3436823T3 (da) Antigen-array
MA46860A (fr) Inhibiteurs de magl
DK3335532T3 (da) Tandharve
DK3402792T3 (da) Quinolin-2-on-derivater
DK3445708T3 (da) Stigbøjle
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
EP3402021A4 (en) GRAB WIRE
DK3452590T3 (da) Plademagnet
BR112017022691A2 (pt) inibidor de bromodomínio.
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
EP3683214A4 (en) BRD4 INHIBITOR
DK3575238T3 (da) Pallecontainer
EP3399976C0 (en) BENZOTHIAZOLE AMPHOPHILES
EP3526210A4 (en) BROMDOMAIN INHIBITORS
DK3481826T3 (da) Tyrosinkinaseinhibitorer
DE112017000734A5 (de) Glycolsensor

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190516

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031470000

Ipc: A61K0031472000

A4 Supplementary search report drawn up and despatched

Effective date: 20200519

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 217/22 20060101ALI20200513BHEP

Ipc: A61P 35/00 20060101ALI20200513BHEP

Ipc: A61K 9/16 20060101ALI20200513BHEP

Ipc: C07D 217/24 20060101ALI20200513BHEP

Ipc: A61K 9/20 20060101ALI20200513BHEP

Ipc: A61K 31/472 20060101AFI20200513BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013944

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231017

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240405

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240806

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40013944

Country of ref document: HK